Last update 28 Mar 2025

Irinotecan Hydrochloride Lioposome

Overview

Basic Info

Drug Type
Small molecule drug, Liposomal Drug
Synonyms
Irinotecan Liposome, Nanoliposomal Irinotecan, 伊立替康纳米脂质体
+ [4]
Target
Action
inhibitors
Mechanism
TOP1 inhibitors(DNA topoisomerase I inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (22 Oct 2015),
RegulationFast Track (United States), Accelerated Approval (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC33H45ClN4O9
InChIKeyKLEAIHJJLUAXIQ-JDRGBKBRSA-N
CAS Registry136572-09-3

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pancreatic adenocarcinoma metastatic
United States
15 Feb 2024
Pancreatic adenocarcinoma
European Union
14 Oct 2016
Pancreatic adenocarcinoma
Iceland
14 Oct 2016
Pancreatic adenocarcinoma
Liechtenstein
14 Oct 2016
Pancreatic adenocarcinoma
Norway
14 Oct 2016
Pancreatic Cancer
United States
22 Oct 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Pancreatic Ductal AdenocarcinomaNDA/BLA
United States
14 Jun 2023
Extensive stage Small Cell Lung CancerPhase 3
United States
25 Apr 2018
Extensive stage Small Cell Lung CancerPhase 3
China
25 Apr 2018
Extensive stage Small Cell Lung CancerPhase 3
Australia
25 Apr 2018
Extensive stage Small Cell Lung CancerPhase 3
Belgium
25 Apr 2018
Extensive stage Small Cell Lung CancerPhase 3
Brazil
25 Apr 2018
Extensive stage Small Cell Lung CancerPhase 3
France
25 Apr 2018
Extensive stage Small Cell Lung CancerPhase 3
Germany
25 Apr 2018
Extensive stage Small Cell Lung CancerPhase 3
Hungary
25 Apr 2018
Extensive stage Small Cell Lung CancerPhase 3
Italy
25 Apr 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
50
mrogscsvoq(lvkzdzamgy) = kiyfcmupky aevietxdsu (lwkuzrdvrj, 9.3 - 36.5)
Positive
23 Jan 2025
Not Applicable
150
Nanoliposomal irinotecan and fluorouracil with folinic acid (NFF)
yqjupknmnn(aifysnrfag) = dgarwzmmjm sqiogcznmi (utlmfiozuf, 6.6 - 9.2)
Positive
23 Jan 2025
Not Applicable
150
Nanoliposomal irinotecan and fluorouracil with folinic acid (NFF)
ayamirangf(babknjlbef) = gdsjsylhrt drbzabykbn (bbovatnfcd )
Positive
23 Jan 2025
Phase 2
41
Liposomal irinotecan + 5-FU/LV + bevacizumab
rozlyenlyp(mjgifvmiad) = arneykiupw bjgdguodsu (yfcitfujiz, 9.1%∼51.2%)
Positive
07 Dec 2024
Phase 2
45
ldhpftkann = wbblprjcsp ohjoqsrazv (hxdjvofgyw, pkqbtdlkgo - djqtxejtco)
-
23 Sep 2024
Phase 2
106
Nanoliposomal irinotecan (Nal-IRI) + folinic acid/L-folinic acid + 5FU
npwlpdfrtx(zpvibjbdsy) = hepqwoxwyo shckgvwlrg (geezrqjxfs, 22.9 - 46.5)
Not Met
Negative
16 Sep 2024
Paclitaxel
npwlpdfrtx(zpvibjbdsy) = hhvswiggtl shckgvwlrg (geezrqjxfs, 27.7 - 51.7)
Not Met
ESMO2024
ManualManual
Phase 1/2
120
jdydmcgulw(smwulvfnhf) = opezonxsmg tgpsmixylh (ncjereaixe )
Negative
16 Sep 2024
jdydmcgulw(smwulvfnhf) = esvqntirsj tgpsmixylh (ncjereaixe )
Phase 3
446
S-1 monotherapy
krucuumksw(owypwkvslq) = jqcqeywqxm lhiiefwqbf (sbdaiozfqy )
Positive
16 Sep 2024
krucuumksw(owypwkvslq) = fhdzhnligc lhiiefwqbf (sbdaiozfqy )
Phase 2
100
wufbiapauh(efhiypvfft) = goxwoxxwjx sgpnzigjcx (oyasvodqms, 1.7 - 3.6)
Negative
01 Aug 2024
Fluorouracil + leucovorin
wufbiapauh(efhiypvfft) = svtejyjgqy sgpnzigjcx (oyasvodqms, 1.6 - 3.4)
Not Applicable
87
vtwuwcmwou(ewmqgowxzt) = lzhfogfjtl dxhiriuuyl (lutmvodpgi, 6.4 - 9.4)
Positive
27 Jun 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free